Objective Based on the current evidence, review the efficacy and safety profile of
pembrolizumab, along with its shortcomings, in an effort to define future research directions …

Introduction Esophageal cancer (EC) is the seventh most common cancer and the sixth
leading cause of cancer death. However, the prognosis of unresectable advanced or …

2 Background: Patients with advanced esophageal cancer after first-line chemotherapy
(chemo) have a poor prognosis and limited treatment options. We present results of the …

Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To …

PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited
treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open …

4010 Background: The phase 3 KEYNOTE-181 study compared pembrolizumab (pembro)
vs chemo as second-line therapy for patients (pts) with advanced/metastatic squamous cell …

The prognosis of patients with advanced esophageal cancer (EC) remains poor and there
are limited effective therapeutic agents for EC. Pembrolizumab monotherapy exerts clinically …

4010 Background: Expression of the PD-1 ligands PD-L1 and PD-L2 has been associated
with poor prognosis in esophageal cancer. Pembrolizumab is a highly selective humanized …

TPS4139 Background: PD-L1 is frequently overexpressed in esophageal cancer.
Pembrolizumab is a humanized monoclonal antibody that targets the PD-1 receptor and …

Introduction Esophageal cancer (EC) is the ninth most common cancer in Japanese men.
Esophageal squamous cell carcinoma (ESCC) is the major histological type and accounts …